Vinblastine has 9 known drug interactions based on U.S. FDA drug labeling data. 7 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Aprepitant, Fosaprepitant, Fosaprepitant Dimeglumine. Patients taking Vinblastine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 9
- Major
- 7
- Moderate
- 2
Major (7)
- Vinblastine + Aprepitant— Increased chemotherapeutic agent exposure may increase risk of adverse reactions. Monitor for chemotherapy-related adver…
- Vinblastine + Fosaprepitant— Increased exposure of chemotherapeutic agent may increase risk of adverse reactions. Monitor for chemotherapeutic-relate…
- Vinblastine + Fosaprepitant Dimeglumine— Increased exposure of chemotherapeutic agent may increase risk of adverse reactions. Monitor for chemotherapeutic-relate…
- Vinblastine + Ganciclovir Sodium— Associated with myelosuppression or nephrotoxicity; coadministration should be considered only if potential benefits out…
- Vinblastine + Tolterodine Tartrate— CYP3A4 inhibitor that increases tolterodine plasma concentrations. Dose reduction to 1 mg twice daily recommended.
- Vinblastine + Valganciclovir— Associated with myelosuppression or nephrotoxicity. Coadministration should be considered only if potential benefits out…
- Vinblastine + Valganciclovir Hydrochloride— Co-administration with valganciclovir should be considered only if potential benefits outweigh risks due to potential fo…
Moderate (2)
- Vinblastine + Ganciclovir— Associated with myelosuppression or nephrotoxicity. Coadministration considered only if benefits outweigh risks.
- Vinblastine + Netupitant And Palonosetron— Netupitant inhibits CYP3A4, increasing plasma concentrations of concomitant CYP3A4 substrates for 6 days; avoid concomit…